Gabapentin is most commonly abused by taking far more than a prescribed dose, often in combination with opioids, benzodiazepines, or alcohol, to amplify a euphoric high. The drug was long considered low-risk for misuse because it does not act on the same brain receptors as classic drugs of abuse, but a growing body of evidence shows that roughly one in five people who misuse opioids also misuse gabapentin, and the combination sharply increases the risk of fatal respiratory depression.
How People Take It to Get High
Gabapentin’s absorption in the gut is unusual. Rather than being absorbed passively like most pills, it relies on a specific amino-acid transport system in the intestinal wall that can only shuttle so much drug at a time. That means there is a ceiling: taking a larger dose does not proportionally increase how much enters the bloodstream.
People who misuse gabapentin have figured this out empirically. A common workaround is staggering doses, swallowing one large portion and then taking more every 30 to 60 minutes so the transporter does not get overwhelmed all at once. Others crush tablets and insufflate (snort) them, though nasal absorption of gabapentin is inefficient and the pills are bulky. Regardless of method, the doses involved in misuse far exceed the therapeutic range. Prescriptions typically cap at 1,800 to 3,600 mg per day; reports from people who misuse the drug describe daily intakes of 5,000 mg or more.
The other, arguably more dangerous, pattern is co-ingestion. Many people do not take gabapentin alone for its psychoactive effects. Instead, they layer it on top of an opioid or a benzodiazepine to intensify or extend the high. A systematic review found that gabapentin was primarily misused for recreational purposes or self-medication, and that it was commonly combined with opioids, benzodiazepines, or alcohol.
What the High Feels Like
One reason gabapentin flew under the radar for years is that its subjective effects do not map neatly onto any single drug class. User reports describe an unusual cocktail of sensations: euphoria and increased talkativeness reminiscent of opioids, sedation similar to benzodiazepines, and at high doses, a dissociative or “floaty” quality that some compare to psychedelics.1PubMed Central. Gabapentin misuse, abuse, and diversion: A systematic review That range of effects makes it appealing to different groups for different reasons. Some people seek the calming, anxiolytic feeling; others want to boost the euphoria of another substance.
Pharmacovigilance data from the FDA’s adverse event reporting system paints a similar picture. Compared to duloxetine, a non-abused pain and depression medication used as a benchmark, gabapentin reports showed roughly five times the odds of a co-reported euphoric mood, more than four times the odds of auditory hallucinations, and about three times the odds of being flagged as “drug abuser.”2PubMed Central. Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system Those signals do not prove gabapentin caused each event on its own, since many reports involved other drugs too, but they confirm that misuse-related experiences cluster around this medication in a way they do not around other non-opioid pain drugs.
Who Misuses Gabapentin
Gabapentin misuse is not evenly distributed across the population. In the general public, the rate is low, around one percent according to the systematic review literature.1PubMed Central. Gabapentin misuse, abuse, and diversion: A systematic review Among people who already have an opioid use disorder, the picture is starkly different. A study comparing patients with and without opioid addiction found that about a quarter of opioid-addicted patients endorsed misusing gabapentin, versus just four percent of those without an opioid problem.3PubMed. Abuse of Gabapentin is Associated with Opioid Addiction That gap led the researchers to describe gabapentin abuse as “specific to an opioid-addicted population.”
People with prescriptions for gabapentin also misuse it at rates that would surprise most clinicians. Estimates suggest that somewhere between 40 and 65 percent of individuals who hold a gabapentin prescription use it in ways it was not intended, whether by taking higher-than-prescribed doses, combining it with other substances, or both.1PubMed Central. Gabapentin misuse, abuse, and diversion: A systematic review That figure is striking given how freely the medication is prescribed. Because gabapentin is not a federally controlled substance in most of the United States, it has historically been easier to obtain than opioids or benzodiazepines, sometimes treated as a safer alternative by prescribers trying to move patients away from riskier drugs.
Incarcerated populations are another high-risk group. Research in correctional settings has found that gabapentinoid use correlates strongly with polysubstance use, alcohol and drug addiction histories, and a higher frequency of infirmary and hospital visits. In some facilities, gabapentin and the related drug pregabalin have become sought-after commodities, traded among inmates in pill form.
The Opioid-Gabapentin Combination and Respiratory Depression
The single most dangerous way gabapentin is abused is alongside opioids, and this is where the evidence is clearest that lives are at stake. A large population-based study in Ontario found that people co-prescribed gabapentin and opioids had roughly 49 percent higher odds of an opioid-related death compared to those taking opioids alone, even after adjusting for opioid dose and other confounders.4PLoS Medicine. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study At moderate-to-high gabapentin doses (900 mg per day and above), the odds climbed to about 60 percent higher. These are not trivial numbers. They mean that for every group of opioid users who add gabapentin, a measurable fraction will die who otherwise would not have.
The mechanism behind this danger involves breathing. Opioids suppress the brain’s respiratory drive, which is how most opioid overdoses kill. Gabapentin appears to compound that suppression, and there is experimental evidence suggesting that even a single dose of a gabapentinoid can reverse the tolerance to respiratory depression that chronic opioid users develop.5PubMed. Non-opioid antinociceptive drugs: risk of respiratory depression and death related to concomitant use of gabapentinoids in addition to opioids In practical terms, a person who has been on opioids for months and has built up a tolerance to their sedating and breathing-slowing effects can have that tolerance partially stripped away by adding gabapentin. The opioid dose that was survivable yesterday becomes lethal today.
This is especially insidious because gabapentin is often prescribed alongside opioids deliberately, for chronic pain. The combination is meant to allow a lower opioid dose, but if the patient (or someone who diverts the pills) takes both at high doses, the risk spikes.
What Forensic Data Show About Gabapentin Deaths
Gabapentin now appears frequently in postmortem toxicology reports from drug overdose deaths. A multi-state study found that, on average, about 22 percent of all drug overdose decedents tested positive for gabapentin. Among those who tested positive for opioids specifically, roughly a quarter also had gabapentin in their system.6PubMed. Prevalence of gabapentin in drug overdose postmortem toxicology testing results That prevalence is remarkable for a drug most people still think of as a benign nerve-pain medication.
A review of gabapentin-related fatalities found that most deaths involved several other intoxicants, with opioids, benzodiazepines, over-the-counter medications, and antidepressants commonly present alongside gabapentin.7PubMed. Gabapentin-related Deaths: Patterns of Abuse and Postmortem Levels A separate analysis in Michigan found that in every single case where gabapentin was detected at autopsy (46 out of 180 mixed-drug fatalities), an opiate was also present in the blood or urine.8PubMed Central. Gabapentin in Mixed Drug Fatalities: Does this Frequent Analyte Deserve More Attention? Gabapentin on its own very rarely kills. When it does appear in fatal overdoses, it is almost always in the company of other respiratory depressants.
Gabapentin-only overdoses, while generally not lethal, do produce symptoms. Poison-center case data report drowsiness, dizziness, nausea, rapid heart rate, and low blood pressure in people who take large amounts without other drugs. Most of those patients recover without lasting harm. The lethality enters with polydrug combinations.
Withdrawal and Physical Dependence
One of the less-discussed dangers of gabapentin misuse is what happens when someone stops. Physical dependence can develop even at prescribed doses, and the withdrawal syndrome ranges from uncomfortable to medically dangerous. Common withdrawal symptoms include anxiety, sweating, rapid heartbeat, restlessness, and insomnia. In more severe cases, people experience confusion, agitation, disorientation, and light sensitivity.9American Journal of Health-System Pharmacy. Withdrawal symptoms after gabapentin discontinuation
The most alarming withdrawal complication is seizures. Even though gabapentin is prescribed as an anti-seizure medication, abruptly stopping it can provoke seizures, including status epilepticus, a prolonged seizure that constitutes a medical emergency.10PubMed. Gabapentin withdrawal presenting as status epilepticus This paradox catches many people off guard. A drug taken to prevent seizures can trigger them upon withdrawal, especially when it has been used at high doses or for extended periods. This applies to people who misuse the drug recreationally but also to patients with legitimate prescriptions who discontinue suddenly.
In severe cases, withdrawal can require a prolonged, carefully managed taper. One published case report described an 18-month tapering protocol for a patient with severe gabapentin dependence, illustrating how entrenched the physical dependency can become.11PubMed. Gabapentin dependence and withdrawal requiring an 18-month taper in a patient with alcohol use disorder: a case report Clinicians increasingly recognize that gabapentin should not be stopped cold, particularly in patients who have been on high doses, and that tapering schedules need to be individualized.
Why Gabapentin Was So Easy to Get
For most of its history in the United States, gabapentin has been an unscheduled prescription drug, meaning it is not tracked the way opioids and benzodiazepines are. Doctors could prescribe it without the paperwork and monitoring requirements that surround controlled substances, and pharmacies filled those prescriptions without reporting them to state prescription drug monitoring programs. That regulatory gap made gabapentin exceptionally easy to stockpile, share, or divert. A person could see multiple doctors, receive multiple prescriptions, and no database would flag the overlap.
That landscape has shifted, but unevenly. A comprehensive analysis of state laws through 2024 found that about half of U.S. jurisdictions have enacted some kind of gabapentin policy. Eight states have classified it as a Schedule V controlled substance, the lowest tier, and required reporting to their prescription drug monitoring programs. Another 17 jurisdictions require the prescriptions to be reported but stop short of scheduling the drug.12PubMed Central. A Comprehensive Analysis of Jurisdiction-Specific Laws Related to Scheduling or Required Prescription Drug Monitoring of Gabapentin in the United States, 2016–2024 That still leaves roughly half the country without any gabapentin-specific monitoring. The patchwork means a prescriber in one state faces significant oversight, while one a few miles across a border does not.
Internationally, the response has been somewhat swifter. The United Kingdom reclassified gabapentin as a Class C controlled substance in 2019, making possession without a prescription a criminal offense. Other countries have taken intermediate steps, requiring special prescribing authority or restricting pack sizes. But the U.S. federal government has not followed suit with a national scheduling action, leaving the matter to state legislatures.
How Gabapentin Compares to Pregabalin
Pregabalin (sold as Lyrica) is gabapentin’s pharmacological cousin. Both bind to the same target on voltage-gated calcium channels, and both produce similar subjective effects at recreational doses. But pregabalin is generally considered to have a higher misuse potential. It is absorbed more quickly and more completely than gabapentin because it does not rely on the same saturable gut transporter, so taking a bigger dose actually delivers a bigger high. Pregabalin is also more potent milligram for milligram.
The U.S. recognized this difference early: pregabalin has been a Schedule V controlled substance federally since it was approved in 2004. Gabapentin, despite accumulating evidence of misuse, has never received that federal designation. An international adverse-event database identified nearly 12,000 reports of gabapentinoid abuse between 2004 and 2015, with more than three-quarters of those reports coming after 2012, suggesting the problem accelerated sharply in the last decade.1PubMed Central. Gabapentin misuse, abuse, and diversion: A systematic review The scheduling gap between the two drugs has arguably pushed some misuse toward gabapentin precisely because it is easier to obtain.
Gabapentin Misuse in People Who Are Not Seeking a High
Not all gabapentin misuse is recreational. A meaningful portion of people who take more than prescribed are self-medicating for anxiety, insomnia, or opioid withdrawal symptoms. Gabapentin can blunt the discomfort of early opioid withdrawal, and some people obtain it informally to manage those symptoms when they cannot access medical treatment. In this sense, the drug occupies a complicated position: it is sometimes misused in an attempt to address a legitimate medical problem, but the unsupervised doses and combinations involved still carry real risks.
There is also a diversion concern that extends in unexpected directions. Gabapentin is widely prescribed in veterinary medicine for pain and anxiety in dogs and cats. While veterinary diversion is not a major driver of the overall problem, it has been flagged as a growing concern. As prescribing controls tighten in human medicine, any channel that dispenses the drug without monitoring becomes a potential source.
Detection Gaps
Standard urine drug screens used in emergency rooms, pain clinics, and addiction programs do not detect gabapentin. It is not an opioid, not a benzodiazepine, and not an amphetamine, so it simply does not show up on the immunoassay panels that most facilities use as a first-line test. Detecting gabapentin requires a specific order for expanded testing, typically using a technique like liquid chromatography–mass spectrometry.
This matters for two reasons. First, clinicians evaluating a patient who appears intoxicated or has overdosed may not realize gabapentin is involved unless they specifically think to test for it. Given the evidence that gabapentin amplifies opioid respiratory depression, that blind spot can affect treatment decisions. Second, patients enrolled in medication-assisted treatment programs for opioid addiction can misuse gabapentin without triggering the drug screens meant to monitor their compliance. The drug functionally hides in plain sight.
Some states and treatment programs have started adding gabapentin to their testing panels, but the practice is far from universal. As with scheduling, the response has been slow and inconsistent relative to the speed at which misuse patterns have evolved.
What the Pharmacology Misses
Part of the reason gabapentin misuse blindsided the medical community is that the drug does not behave like a classic substance of abuse in laboratory settings. It does not bind to opioid receptors, does not directly boost dopamine in the reward pathway, and does not produce acute sedation through GABA receptors the way benzodiazepines do. Gabapentin’s primary known action is binding to the alpha-2-delta subunit of voltage-gated calcium channels, which disrupts calcium channel trafficking over time rather than producing an immediate, dramatic change in neurotransmission.13Proceedings of the National Academy of Sciences. Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin Acute inhibition of calcium currents by gabapentin is either very minor or absent, which led early researchers to reasonably conclude that the drug had minimal abuse liability.
That conclusion was wrong in practice, even if it made sense mechanistically. The disconnect likely reflects how much we still do not understand about what makes a drug rewarding to the human brain. Laboratory animal models that reliably predict abuse potential for opioids and stimulants performed poorly for gabapentin. The real-world signal came from patients, correctional facilities, forensic toxicology labs, and street-level reports long before the pharmacology caught up. It is a useful reminder that a drug’s mechanism of action on paper does not always predict what people will do with it in the real world.